AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00753441 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic stenting
Description: Placement of a biliary metal stent (in combination with a duodenal metal stent in case of gastric outlet obstruction if necessary)
Study NCT01513317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siltuximab
Description: 15 mg/kg administered as a 1-hour intravenous infusion every 4 weeks
Study NCT01513317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as a 1-hour intravenous infusion every 4 weeks
Study NCT01513317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Best supportive care (BSC)
Description: Best supportive care according to local standards and guidelines
Study NCT01653431 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Study NCT01653431 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Study NCT01816620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide, Dexamethasone
Description: 12 cycles of lenalidomide and dexamethasone, each cycle lasts 28 days. For patients with Ccr equal to or higher than 30ml/min, oral lenalidomide 10mg once daily for days 1-21 out of a 28 cycle.~For patients with Ccr lower than 30ml/min, oral lenalidomide 10mg once every other day for days 1-21 out of a 28 cycle.~All the patients take Dexamethasone orally 40mg once weekly for day 1,8,15,22 out of a 28 cycle.
Study NCT01032694 — intervention group
Intervention type: DRUG
Intervention: Azithromycin SR
Description: Azithromycin SR, 2.0 g PO x 1 dose for treatment period
Study NCT01032694 — intervention group
Intervention type: DRUG
Intervention: Amoxiclav
Description: Amoxiclav 1000 x twice daily, 10 days duration
Study NCT02864017 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Enteral nutrition
Study NCT02864017 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Study NCT02864017 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Citrulline
Study NCT02864017 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00637546 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Gait and Balance training based on recommendations of Robertson et al. and Page et al. (different balance control exercises; progression in consecutive stages: Sensimotor training, a static phase, a dynamic phase combined with functional tasks. The treatment takes place twice a week over 12 weeks. Patients were encouraged to perform specific home exercises.
Study NCT01311830 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Counseling
Study NCT03489239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide
Description: subjects switching from Entecavir to single arm TAF 25mg
Study NCT01889927 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Intervention
Description: The exercise intervention will include aerobic, anaerobic, strength, core conditioning and stretching components.
Study NCT01311830 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Written Materials
Study NCT03063229 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Accelerometer
Description: Attach a monitor to participants thigh to measure their physical activity for 7 days. The monitor is called the Activpal Micro.
Study NCT03063229 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accelerometer
Description: Attach a monitor to participants thigh to measure their physical activity for 7 days. The monitor is called the Activpal Micro.
Study NCT03063229 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Anthropomentry
Description: Take skinfold measurements of participants using Harpenden skinfold calipers.
Study NCT03063229 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Anthropomentry
Description: Take skinfold measurements of participants using Harpenden skinfold calipers.
Study NCT03063229 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood tests
Description: Taking standard clinical blood tests to measure HbA1c, Glucose, FBC, U\&E's, LFT's, Coagulation Screen, Lipid Profile, Thyroid Function, and Tacrolimus for transplant patients.
Study NCT03063229 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood tests
Description: Taking standard clinical blood tests to measure HbA1c, Glucose, FBC, U\&E's, LFT's, Coagulation Screen, Lipid Profile, Thyroid Function, and Tacrolimus for transplant patients.
Study NCT03063229 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: BODPOD
Description: Measure body composition using a BODPOD machine. This uses Air displacement plethysmography.
Study NCT03063229 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BODPOD
Description: Measure body composition using a BODPOD machine. This uses Air displacement plethysmography.
Study NCT01154673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltegravir
Description: Raltegravir 400 mg BID + Maraviroc 150mg BID in addition to standard HAART
Study NCT01154673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: maraviroc
Description: Raltegravir 400 mg BID + Maraviroc 150mg BID in addition to standard HAART
Study NCT03063229 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRI (Magnetic Resonance Imaging)
Description: MRI Scans of abdomen, particularly the livers of islet transplant and insulin pump patients.
Study NCT03063229 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Food Diary
Description: Participants will keep a 7 day weighed food diary.
Study NCT01154673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: emtricitabine 200mg /tenofovir 300mg
Description: emtricitabine 200mg /tenofovir 300mg QD
Study NCT01154673 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: emtricitabine 200mg /tenofovir 300mg
Description: emtricitabine 200mg /tenofovir 300mg QD
Study NCT01154673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lopinavir 400 mg/ritonavir 100mg
Description: lopinavir 400 mg/ritonavir 100mg BID
Study NCT03063229 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Food Diary
Description: Participants will keep a 7 day weighed food diary.
Study NCT03063229 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CGMS (Continuous Glucose Monitoring System)
Description: Participants will wear a CGMS for 7 days to measure their glucose control and pattern over a 7 day period.
Study NCT01154673 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lopinavir 400 mg/ritonavir 100mg
Description: lopinavir 400 mg/ritonavir 100mg BID
Study NCT01850108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: Day 9 before BMT: 0.5mg/kg IV; Days 8 \& 7 before BMT: 2mg/kg IV~Days 8 \& 7 - 2mg/kg IV before BMT
Study NCT01850108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Days 6 and 2 before BMT: 30mg/m2/day IV
Study NCT01850108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CTX)
Description: Days 6 and 5 before BMT: 14.5mg/kg IV; Days 3 and 4 after BMT: 50mg/kg/day
Study NCT01850108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Days 3 \& 4 after BMT: 40 mg/kg IV
Study NCT01850108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Adjusted to maintain a serum trough level of 3-12 ng/mL, taken orally beginning on 5 days after BMT and taken to 1 year after BMT.
Study NCT01850108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Description: 15 mg/kg orally with maximum dose 3 mg/day beginning 5 days after BMT and taken to day 35 after BMT
Study NCT01850108 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation
Description: Day 0 - Transplantation of hematopoietic cells derived from bone marrow of a donor to a recipient as treatment for hematologic disorders
Study NCT01850108 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation
Description: 200 cGy on the day before BMT. Radiation delivered to the entire body of the recipient to eradicate bone marrow cells in the recipient to prepare the recipient to receive the transplanted
Study NCT05059717 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo standard of care MRI
Study NCT05059717 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MR DENSE imaging
Study NCT02765542 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Automated disease assessment & self-care support phone calls
Description: Automated disease assessment \& self-care support phone calls for up to 12 weeks.
Study NCT03311828 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given IV
Study NCT03311828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imaging Agent
Description: Given Copper 64Cu-DOTA-daratumumab IV
Study NCT03311828 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET
Study NCT03311828 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01636258 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culinary education
Description: Every other week
Study NCT02637362 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ankle block
Description: Ultrasound guided ankle block of the tibial, superficial peroneal and deep peroneal nerves will be performed using a standardised technique
Study NCT05347407 — intervention group
Intervention type: PROCEDURE
Intervention: Colonoscopy
Description: Patients will be provided with a kit and be asked to bring a stool sample to their colonoscopy appointment. Mucosal biopsies will be collected with standard forceps during colonoscopy. If the physician determines that the patient will need colonoscopy with biopsy as part of their routine clinical care, they will take 6-8 additional biopsies for use in the research study. If the physician determines that the patient will need colonoscopy without biopsy as part of their routine clinical care, they will take 6-8 biopsies for use in the research study only. The collection of additional biopsies will add an estimated two minutes to the whole procedure.
Study NCT04064359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBT076, a CD205-directed antibody-drug conjugate
Description: Intravenous (IV) infusion of OBT076 every 3 weeks.
Study NCT03063229 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CGMS (Continuous Glucose Monitoring System)
Description: Participants will wear a CGMS for 7 days to measure their glucose control and pattern over a 7 day period.
Study NCT03063229 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire and Hypo Score
Description: Participants with Type 1 Diabetes will fill in 3 short questionnaires about their Diabetes.
Study NCT03063229 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Mixed Meal Tolerance Test (MMTT)
Description: The patients will under go a test which involves taking 30 minute glucose and C-peptide levels (blood test from a cannula) for 3 hours. They will consume 150ml of a mixed meal supplement drink Fortisip Compact at the start of the 3 hours, after having no morning insulin, breakfast and not eating anything from midnight the night before.
Study NCT03063229 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mixed Meal Tolerance Test (MMTT)
Description: The patients will under go a test which involves taking 30 minute glucose and C-peptide levels (blood test from a cannula) for 3 hours. They will consume 150ml of a mixed meal supplement drink Fortisip Compact at the start of the 3 hours, after having no morning insulin, breakfast and not eating anything from midnight the night before.
Study NCT03063229 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Indirect Calorimetry
Description: During the Meal Tolerance Test, the patients will be resting on a bed in the research facility and breathing normally into a clear plastic hood. The machine connected to the hood (GEM) will analyse their resting energy expenditure from the gases expired in their breath. They will have the hood on for 2 hours.
Study NCT03063229 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Indirect Calorimetry
Description: During the Meal Tolerance Test, the patients will be resting on a bed in the research facility and breathing normally into a clear plastic hood. The machine connected to the hood (GEM) will analyse their resting energy expenditure from the gases expired in their breath. They will have the hood on for 2 hours.
Study NCT03063229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doubly Labelled Water
Description: The Doubly Labelled water will be prescribed for the participants and they will drink their 100ml dose of the stable isotope. Dose depends on the eight of the participant. The participant will then collect urine samples at home on day 5, 10 and 14 after drinking the water. They will store them in the freezer until they can bring them back to us.
Study NCT03063229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hepatic Mitochondrial Oxidation breath test
Description: Participants will be given a calculated amount of the stable isotope C-Octanoate, which will be delivered in a water solution. They will then be asked to breath down a small tube into a clear plastic collection bag 10 times over 2 hours.
Study NCT05754320 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tension band wire fixation
Description: Tension band wire fixation
Study NCT05754320 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plate fixation
Description: Tension band wire fixation
Study NCT01557660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled treprostinil
Description: 0.6mg/mL inhalation solution, up to 12 breaths four times a day
Study NCT03529526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN046
Description: The modified phase I 3 + 3 study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of KN046: 0.3 mg/kg,1 mg/kg,3 mg/kg,5 mg/kg,10 mg/kg.
Study NCT03383432 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Intrauterine device
Description: Copper T 380 A
Study NCT02637362 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sham ankle block
Description: In the supine position with the hip and knee flexed, and the hip externally rotated, the skin from medial malleolus to Achilles tendon will be prepared with chlorhexidine 0.5% solution and allowed to dry. An ultrasound probe (linear array HFL25, Sonosite, Hitchin, UK) will be placed on a line from medial malleolus to achilles tendon to identify the posterior tibial artery and tibial nerve. A Stimuplex A50 needle (B-Braun) will be placed against the skin at the point at which the practitioner would normally have performed insertion of the needle. It will remain there for a total of 30 seconds and then will be removed.
Study NCT03383432 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Ultrasound
Description: Transabdominal ultrasound
Study NCT03383432 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: uterine sounding sparing technique
Description: we will insert intrauterine device without using the uterine sound and we will replace this step by ultrasound before insertion
Study NCT03548844 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: local excision
Description: Pathologically verified ypT0-1cN0 rectal cancer patients after local excision are randomized to observation (local excision group) .
Study NCT03548844 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total mesorectal excision
Description: Pathologically verified ypT0-1cN0 rectal cancer patients after local excision are randomized to complementary rectal excision (total mesorectal excision group).
Study NCT00023673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study NCT01149083 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT01149083 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT02637362 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Metatarsal block
Description: A metatarsal block will be performed using a standardised technique
Study NCT02637362 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sham metatarsal block
Description: In the supine position, after the surgical incision has been sutured, a 25G standard bevel needle will be placed against the skin at the points at which the practitioner would normally have performed insertions of the needle. It will remain there for a total of 30 seconds and then be removed.
Study NCT01149083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT01149083 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT01149083 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT01149083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study NCT04366492 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Prevalence of blood borne viral infections (HBV/HCV/HIV)
Description: rapid finger prick test for HCV Ab, HBsAg and HIV and a questionnaire
Study NCT04288323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid
Description: This study involves an on-label use of Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid for the ....
Study NCT00023673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study NCT02766686 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy with protons
Study NCT02766686 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy with photons
Study NCT02766686 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Radiotherapy with photons
Study NCT00954694 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NuStep fitness apparatus
Description: The NuStep is a mode of exercise that has recently been used in clinical settings to determine appropriate intensity recommendations and energy expenditures. The NuStep exercise implement provides simultaneous upper and lower body movement while in a seated position. The machine stimulates all major muscle groups while putting minimal strain on joints. Ten resistance settings are offered and the device is fully adjustable to accommodate users of varying sizes (NuStep, 2009).
Study NCT03345485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinostamustine 60mg/m2 over 30min
Description: Tinostamustine as a single agent was administered at doses of 60mg/m2 by intravenous infusion over 30 minutes on Days (D) 1 and 15 of each 28-day cycle.
Study NCT03345485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinostamustine 80mg/m2 over 30min
Description: Tinostamustine as a single agent was administered at doses of 80mg/m2 by intravenous infusion over 30 minutes on Days (D) 1 and 15 of each 28-day cycle.
Study NCT03345485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinostamustine 100mg/m2 over 30min
Description: Tinostamustine as a single agent was administered at doses of 100mg/m2 by intravenous infusion over 30 minutes on Days (D) 1 and 15 of each 28-day cycle.
Study NCT03345485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinostamustine 60mg/m2 over 60min
Description: Tinostamustine as a single agent was administered at doses of 60mg/m2 by intravenous infusion over 60 minutes on Days (D) 1 and 15 of each 28-day cycle.
Study NCT00023673 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: three-dimensional conformal radiation therapy
Study NCT03345485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinostamustine 80mg/m2 over 60min
Description: Tinostamustine as a single agent was administered at doses of 80mg/m2 by intravenous infusion over 60 minutes on Days (D) 1 and 15 of each 28-day cycle.
Study NCT03843502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kava Dietary Supplement
Description: Participants will be given three 75mg kava capsules.
Study NCT03845257 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling, FeNO, bronchoalveolar lavage, bronchoscopic tissue sampling
Description: Blood sampling (eosinophil count; eosinophilia is defined as >300/µl (or >150/µl during oral glucocorticosteroid treatment); FeNO: Measurement of fractional nitric oxide (NO) concentration in exhaled breath; Bronchoscopy: BAL: total leukocyte counts and leukocyte differential counts including eosinophils, PSB sampling: eosinophil count/100 cells, endobrochial biopsy: tissue eosinophil count/100 cells.
Study NCT03783351 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: CYP2C19 genotype testing
Description: CYP2C19 genotype testing will be conducted in a designated central laboratory.